INTRODUCTION
Diabetes Mellitus (DM) is a rapidly growing chronic and multifactorial disease with a worldwide projection of 324 million diabetics by the year 2025 (1) . In Africa, the prevalence of diabetes is expected to rise by 98%, from 13.6 million at 2003 to 26.9 million at 2025. A similar increase (97%) is expected in the Middle East region with an estimated prevalence of 35.9 million diabetics by 2025.
This emphasizes the health and economic threat diabetes poses in these countries as well as the importance of having recognized guidelines for the management of diabetes in order to prevent the Libyan Journal of Medicine, Volume 1, 2006 ljm complications and ensure a normal quality of life to the patients. The prevalence of DM in Libya is not precisely known; although it has been estimated to be as high as 14.1% (prevalence of total glucose intolerance was 22.6%) (2) . In this article, we briefly discuss the basic management of diabetes in adults directed mainly to medical students and junior colleagues. However, the different phases (and complications) of diabetes are beyond the scope of this review. Antibodies:
Is it diabetes?
e.g. GAD65Ab (glutamic acid decarboxylase-65 antibody) and ICA-ab (islet cell antibody), their presence indicates autoimmunity as in type 1. HbA1c, serum creatinin, serum lipids (total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides) and urinary albumin.
Annual follow up:
History: Ask for symptoms of hyperglycemia or hypoglycemia, blood glucose values from patients self controls, symptoms of complications, and actual treatment and doses. Weight loss in uncontrolled diabetic may indicate the need for insulin treatment.
Examination: the patient should be examined for BMI, rest pulse, blood pressure (lying and standing), and signs of complications. Fundal examination by an ophthalmologist must be performed annually for patients with type 1, and biannually for patients with type 2. When retinopathy changes are detected, examination is repeated more often in accordance with an ophthalmologist's recommendations.
Laboratory investigations: HbA1c (4 times/yr), serum creatinin, serum lipids, and urinary albumin.
HbA1c (4 times/yr), serum creatinin, serum lipids, and urinary albumin.
ECG: for all patients with type 2 diabetes and patients with type 1 diabetes at 40 years or older with at least one cardiovascular risk factor (hypertension, hyperlipidemia, albuminuria, smoking or ischemic heart disease).
Current treatment of diabetes mellitus:
Patient education: in all types of diabetes.
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Diet treatment: in all types of diabetes.
Physical training: in all types of diabetes. It reduces weight, central obesity, and blood lipids while improving insulin sensitivity, thus improving plasma glucose.
Stop smoking: in all types of diabetes.
Acetylsalicylic acid: 75-160mg daily should be considered for all patients with type 2 DM, and patients with type 1 DM older than 40 years with at least one cardiovascular risk factor.
Oral antidiabetics:
Insulin secretion stimulators: Sulphonylureas: An old class, less often used nowadays due to risk of hypoglycemia. They are long acting drugs with less effect on post-prandial hyperglycemia. Examples of this class: Glibenclamide (Daonil), Glipizide (Mindiab) and Glimepiride (Amaryl).
Metiglinides: A relatively new group of drugs. They are preferred over sulphonylureas, as they have shorter duration of action, pose less risk for hypoglycemia, and are more effective on postprandial hyperglycemia, even when pre-prandial glucose values are acceptable. They are given before meals. Examples of this class: Repaglinide (Novonorm) and Nateglinide (Starlix).
Insulin sensitizers:
Biguanides: Metformin is the only drug in this group. It is widely used and considered first line treatment in DM type 2. Gastrointestinal side effects are common but avoidable by slow up titration of doses.
Thiazolidinediones (Glitazones):
Examples of this class: Rosiglitazone (Avandia) and Pioglitazone (Actos). Side effects are weight gain and fluid retention. Maculoedema has also been reported.
α glucosidase inhibitor:
Acarbose (Glucobay): It has limited use due to gastrointestinal side effects.
Insulin:
Short acting human insulin: its use is mostly limited now to acute situations where intravenous insulin infusion or intramuscular injections are needed e.g. Diabetic ketoacidosis or hyperosmolar non-ketotic coma. Example of 
Drug treatment strategy:
Type 1 diabetes (absolute insulin deficiency):
Multiple insulin injections:
Rapid acting insulin (Novorapid/ Humalog) at meal time and Lantus once at night as base insulin is the mostly used regimen. Lantus can also be given at any time during the day e.g. morning, at lunch, or in the evening. As alternatives to Lantus, Insulatard or Detemir can be used once or www.ljm.org.ly ljm twice daily. Regular blood sugar self controls are strongly recommended. A whole day profile (at breakfast, lunch, evenings meal and bedtime) 1-2 times/week is preferred.
In cases with insulin deficiency in elderly patients [DM type 1, latent autoimmune diabetes in adults (LADA) or secondary diabetes to pancreas diseases], a more simple insulin regimen can be used instead, e.g. 2 doses of mixed insulin daily.
Insulin pump: Continuous subcutaneous insulin infusion (CSII) can be considered in insulin dependent patients with good compliance and sufficient education.
TYPE 2 DIABETES (RELATIVE-LY PRESERVED INSULIN SE-CRETION):
Diet and physical training: is the first line treatment. Regular blood sugar self controls should be used. If blood glucose is still not controlled, add treatment in next step. There is an ongoing discussion in Sweden in order to lower the level of treatment goals: HbA1c 6.8% in type 1, HbA1c 5.9-6.8% in type 2 (lower HbA1c in type 2 due to less risk for hypoglycemia), serum total cholesterol <170 mg/dl and blood pressure in patients with nephropathy <120/70 mmHg. The reason for this additional tightening of treatment goals is the occurrence of complications at low HbA1c levels (>5.9%).
To apply these goals is practi-www.ljm.org.ly ljm cally difficult, but the patient is ultimately the beneficiary. Again, individualization of the treatment is of extreme importance in the management of patients with diabetes. The self-control of blood glucose by patients and education of both patients and diabetes health care teams are the most important steps to be considered by colleagues and authorities to improve the diabetes care.
